东富龙 reported revenue of ¥2.53B for the period ended 2026-06-30, +4.4% year on year. Net income was ¥0.13B, a 5.1% net margin on a 32.2% gross margin. The largest revenue line is 制剂装备事业部 at 44% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.53B | +4.4% |
| Gross profit | ¥0.82B | — |
| Operating income | ¥0.14B | — |
| Net income | ¥0.13B | +158.9% |
| Gross margin | 32.2% | Net margin 5.1% |
| Revenue Q/Q | +28.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 制剂装备事业部 | ¥1.11B | 43.8% |
| 生物工艺装备及耗材事业部 | ¥0.72B | 28.3% |
| 制药工程事业部 | ¥0.29B | 11.6% |
| 食品工程及装备事业部 | ¥0.26B | 10.1% |
| 售后服务与配件 | ¥0.16B | 6.1% |
| 其他业务收入 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.72B | 67.8% |
| R&D | ¥0.14B | 5.7% |
| SG&A | ¥0.41B | 16.2% |
| Tax & other | ¥0.01B | 0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥13.61B |
| Total liabilities | ¥5.38B |
| Shareholders' equity | ¥8.23B |
| Equity / assets | 60.5% |
| Operating cash flow | ¥0.12B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 71% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中电环保 ・ ST福能 ・ 元力股份 ・ 朗源股份 ・ 鸿特科技 ・ 中海达 ・ 四方达 ・ 华峰超纤 ・ 佐力药业 ・ 捷成股份 ・ 东软载波 ・ 力源信息
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies